GeneDx Holdings Corp. (WGS): A Bull Case Theory

We came across a thesis on GeneDx Holdings Corp. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on WGS. GeneDx Holdings Corp.'s share was trading at $92.04 as of February 18th. WGS’s trailing and forward P/E were 819.55 and 77.52 respectively according to Yahoo Finance.

create jobs 51/Shutterstock.com

GeneDx is emerging as a high-growth genomics diagnostics company with a differentiated clinical dataset and proprietary interpretation IP that supports strong diagnostic yield, particularly in rare-disease exome and genome testing. The business benefits from structural resilience, as healthcare spending is large and relatively insulated from broader economic cycles, while regulatory tailwinds—most recently the FDA’s Breakthrough Device designation for ExomeDx™ and GenomeDx™ tests—accelerate payer engagement and adoption.

Q3 2025 results underscore strong fundamentals, with revenue of $116.7 million, roughly 65% year-over-year growth in exome/genome test revenue, and adjusted net income of ~$14.7 million, reflecting several consecutive quarters of improving profitability and operating leverage. GeneDx conducted ~25,700 exome/genome tests in Q3, contributing to 41% of total testing volumes year-to-date, highlighting unit-scale as the primary revenue driver. Management has raised full-year guidance, signaling confidence in continued growth, margin expansion (~74% gross margin in Q3), and disciplined capital allocation in the lab’s operationally intensive scaling process.

While competitive pressures exist from large integrated diagnostics and platform players, the proprietary variant database and clinical curation provide a moderately durable moat that strengthens payer discussions. Key near-term risks include reimbursement delays, lab capacity constraints, and operational disruptions, all of which could materially impact volume-driven revenue. Catalysts include broader commercial payer coverage, accelerating exome/genome volumes, continued adjusted profitability, positive real-world evidence publications, and FDA engagement.

Given current growth and improving margins, GeneDx offers favorable asymmetric upside if reimbursement and scale continue, while a conservative portfolio allocation (0.5–1%) allows monitored exposure, with upside conviction (1–3%) contingent on careful tracking of payer developments, test volumes, and operational execution. Overall, the company represents a compelling, policy- and regulation-driven growth story in genomics diagnostics.

Previously, we covered a 

 on Thermo Fisher Scientific Inc. (TMO) by FluentInQuality in March 2025, which highlighted the company’s recurring consumables revenue, strong capital efficiency, and durable positioning in laboratory solutions. TMO's stock price has depreciated by approximately 1.92% since our coverage. Danny Green shares a similar view but emphasizes on GeneDx Holdings Corp.’s genomics growth and regulatory tailwinds.

GeneDx Holdings Corp. is not on our list of the 

. As per our database, 34 hedge fund portfolios held WGS at the end of the third quarter which was 30 in the previous quarter. While we acknowledge the risk and potential of WGS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WGS and that has 10,000% upside potential, check out our report about this cheapest AI stock

30 Stocks That Should Double in 3 Years 11 Hidden AI Stocks to Buy NOW